Regenxbio Inc (RGNX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Regenxbio Inc stock (RGNX) is currently trading at $7.81. Regenxbio Inc PS ratio (Price-to-Sales) is 2.53. Analyst consensus price target for RGNX is $27.82. WallStSmart rates RGNX as Underperform.
- RGNX PE ratio analysis and historical PE chart
- RGNX PS ratio (Price-to-Sales) history and trend
- RGNX intrinsic value — DCF, Graham Number, EPV models
- RGNX stock price prediction 2025 2026 2027 2028 2029 2030
- RGNX fair value vs current price
- RGNX insider transactions and insider buying
- Is RGNX undervalued or overvalued?
- Regenxbio Inc financial analysis — revenue, earnings, cash flow
- RGNX Piotroski F-Score and Altman Z-Score
- RGNX analyst price target and Smart Rating
Regenxbio Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Regenxbio Inc (RGNX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, revenue growth, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Regenxbio Inc (RGNX) Key Strengths (3)
Growing significantly faster than its price suggests
Revenue surging 43.00% year-over-year
81.16% of shares held by major funds and institutions
Supporting Valuation Data
Regenxbio Inc (RGNX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Premium pricing at 4.1x book value
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.53x sales
Regenxbio Inc (RGNX) Detailed Analysis Report
Overall Assessment
This company scores 44/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 3 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Revenue Growth, Institutional Own.. Valuation metrics including PEG Ratio (0.26) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 43.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (2.53), Price/Book (4.07) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -107.00%, Operating Margin at -190.00%, Profit Margin at -113.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -107.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 43.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RGNX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RGNX's Price-to-Sales ratio of 2.53x sits near its historical average of 2.66x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 12% below its historical high of 2.87x set in Mar 2026, and 0% above its historical low of 2.53x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~2.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Regenxbio Inc (RGNX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Regenxbio Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 170M with 43% growth year-over-year. The company is currently unprofitable, posting a -113.7% profit margin.
Key Findings
Revenue growing at 43% YoY, reaching 170M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 35% of revenue (60M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -113.7% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -53M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Regenxbio Inc maintain 43%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Regenxbio Inc.
Bottom Line
Regenxbio Inc is a high-conviction growth story with revenue accelerating at 43% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -113.7% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(20 last 3 months)
| Insider | Type | Shares |
|---|---|---|
PAKOLA, STEVE Chief Medical Officer | Sell | -5,124 |
Data sourced from SEC Form 4 filings
Last updated: 8:28:07 AM
About Regenxbio Inc(RGNX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.